PDCD1 and metastatic melanoma: Examples are ipilimumab, a mAb directed against the receptor cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), or pembrolizumab (MK-3475), a mAb against the programed cell death protein-1 (PD-1), used for the treatment of metastatic melanomas (215).